Febrile Neutropenia: Clinical Trials

22 trials for Febrile Neutropenia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 4 unknown, 2 active not recruiting, 2 recruiting. 22 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 222Completed 11, Unknown 4, Active not recruiting 2, Recruiting 2, Terminated 2, Not yet recruiting 1
Phase 13Completed 3
Phase 31Unknown 1

Follow Febrile Neutropenia: new trials by email Literature Review of Febrile Neutropenia trials Research Report on Febrile Neutropenia

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM)
Phase 2Not yet recruitingZealand University Hospital1502027-03-012026-09-25
Phase II Study of QLC2519 in Pediatric Solid Tumor Participants
Albipagrastim alf - Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN)
Phase 2RecruitingQilu Pharmaceutical Co., Ltd.182026-06-262026-07-24
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents - Myelosuppression, Thoracic Neoplasms
Phase 2RecruitingAffiliated Hospital of Nantong University302025-08-012025-12-11
A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
Efgbemalenograstim alfa - Non Small Cell Lung Cancer
Phase 2UnknownTianjin Medical University Cancer Institute and Hospital992023-12-312023-11-22
Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy
Day 7 regimen, Day 3 regimen - Breast Cancer
Phase 2CompletedThe First Affiliated Hospital with Nanjing Medical University1602021-07-132023-02-23
Pentaglobin in CRE and PA Neutropenic Infections
Pentaglobin - Septic Shock
Phase 2Active not recruitingGruppo Italiano Trapianto di Midollo Osseo1202019-12-062025-01-06
Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial
Anakinra, Placebos - Multiple Myeloma
Phase 2CompletedRadboud University Medical Center882019-11-042024-11-18
Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer
EC-18 - Febrile Neutropenia
Phase 1 / Phase 2CompletedEnzychem Lifesciences Corporation282017-10-302026-11-04
Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia
Magnesium Oxide Supplement - Febrile Neutropenia
Phase 2UnknownUniversidad Nacional Autonoma de Mexico2142017-10-192018-03-05
Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT
Anakinra - Multiple Myeloma
Phase 2CompletedRadboud University Medical Center92017-08-212024-11-18
Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
Piperacillin-tazobactam, cefepime - Intestinal Microbiome, Febrile Neutropenia
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center3472017-02-102026-03-04
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
CAZ-AVI, Vancomycin, Linezolid - Neoplasms, Febrile Neutropenia
Phase 2TerminatedForest Laboratories22016-05-172017-07-21
Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
Filgrastim, Peg-filgrastim - Breast Cancer, Neutropenia
Phase 2TerminatedAsan Medical Center222016-02-012020-07-31
Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML
G-CSF - Leukemia, Myeloid, Acute
Phase 2 / Phase 3UnknownSeoul St. Mary's Hospital562015-03-012015-04-28
Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy
YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle - Non Small Cell Lung Cancer, Breast Cancer
Phase 2CompletedXiamen Amoytop Biotech Co., Ltd.802013-12-012018-07-17
Study of Danggui Buxue Decoction in Preventing Neutropenia
DBD, Epirubicin, Cyclophosphamide - Grade 3/4 Neutropenia, Febrile Neutropenia
Phase 2CompletedShanghai Jiao Tong University School of Medicine502013-10-012015-12-30
A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer
PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg) - Advanced Metastatic (Stage IV) Colorectal Cancer
Phase 1 / Phase 2CompletedEgetis Therapeutics AB (publ)1862012-09-012018-07-06
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
empegfilrastim, filgrastim - Chemotherapy-induced Neutropenia
Phase 2CompletedBiocad602012-05-012016-12-05
Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
Micafungin sodium, Itraconazole - Febrile Neutropenia, Hematological Diseases
Phase 2CompletedYonsei University1532011-06-012014-12-08
A Phase II Study Comparing Pegylated rhG-CSF(HHPG-19K) and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy
Pegylated rhG-CSF 100μg/kg, Pegylated rhG-CSF:150 μg/kg, rhG-CSF 5 μg/kg/day - Breast Cancer, Neutropenia
Phase 2CompletedJiangsu HengRui Medicine Co., Ltd.1822011-02-012014-04-22

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Neutropenia (9)  ·  Breast Neoplasms (6)  ·  Multiple Myeloma (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Mucositis (2)  ·  Neoplasms (2)  ·  Colorectal Neoplasms (1)  ·  Fever (1)  ·  Hematologic Diseases (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lung Neoplasms (1)  ·  Pseudomonas Infections (1)  ·  Shock, Septic (1)  ·  Thoracic Neoplasms (1)

Broader conditions

Agranulocytosis (22)  ·  Cytopenia (22)  ·  Hemic and Lymphatic Diseases (22)  ·  Leukocyte Disorders (22)  ·  Leukopenia (22)  ·  Hematologic Diseases (21)  ·  Neoplasms (13)  ·  Neutropenia (13)  ·  Neoplasms by Site (9)  ·  Breast Diseases (6)  ·  Skin Diseases (6)  ·  Skin and Connective Tissue Diseases (6)  ·  Neoplasms by Histologic Type (4)  ·  Blood Protein Disorders (3)  ·  Cardiovascular Diseases (3)

Interventions

Filgrastim (3)  ·  pegylated granulocyte colony-stimulating factor (3)  ·  Cefepime (2)  ·  Interleukin 1 Receptor Antagonist Protein (2)  ·  Piperacillin, Tazobactam Drug Combination (2)  ·  Anidulafungin (1)  ·  Ceftazidime (1)  ·  Ciprofloxacin (1)  ·  Cyclophosphamide (1)  ·  Docetaxel (1)  ·  Epirubicin (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Itraconazole (1)  ·  Linezolid (1)  ·  Meropenem (1)

Sponsors

Radboud University Medical Center (2)  ·  Affiliated Hospital of Nantong University (1)  ·  Asan Medical Center (1)  ·  Biocad (1)  ·  Egetis Therapeutics AB (publ) (1)  ·  Enzychem Lifesciences Corporation (1)  ·  Forest Laboratories (1)  ·  Gruppo Italiano Trapianto di Midollo Osseo (1)  ·  Jiangsu HengRui Medicine Co., Ltd. (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Pfizer (1)  ·  Qilu Pharmaceutical Co., Ltd. (1)  ·  S&D Pharma SK s.r.o. (1)  ·  Seoul St. Mary's Hospital (1)  ·  Shanghai Jiao Tong University School of Medicine (1)

Countries

China (7)  ·  South Korea (4)  ·  United States (4)  ·  Denmark (2)  ·  Netherlands (2)  ·  Bulgaria (1)  ·  Georgia (1)  ·  Germany (1)  ·  Italy (1)  ·  Mexico (1)  ·  Portugal (1)  ·  Russia (1)  ·  Serbia (1)  ·  Slovakia (1)  ·  Sweden (1)

Top investigators

Nicole Blijlevens, MD PhD (2)  ·  Bart Biemond, MD PhD (1)  ·  David Melnick, M.D. (1)  ·  Fabio Ciceri (1)  ·  Gerwin Huls, MD PhD (1)  ·  Jae-Ho Yoon (1)  ·  Kunwei Shen, Dr (1)  ·  Marie Bengtson (1)  ·  Martijn Bakker, MD (1)  ·  Michal Mego, MD, PhD (1)  ·  Miguel A Palomo, PhD (1)  ·  Pavel Bician, MD (1)  ·  Roman A. Ivanov, MD, PhD (1)  ·  Sung-Bae Kim, MD, PhD (1)

Results publications

PMID 29140155, PMID 33030582, PMID 33225965, PMID 35546555, PMID 39533204

NIH funding

2018 (1)